APP’s Better Half? Soluble Fragment Activates Protective Genes
experiments we performed in the sAPPβ ki/ki mice, this was not a major pathway for sAPPβ clearance.”—Esther
379 RESULTS
You searched Esther
Sort By:
experiments we performed in the sAPPβ ki/ki mice, this was not a major pathway for sAPPβ clearance.”—Esther
carriers ultimately show slower rates of mental decline, compared to people with E3 or E4 alleles.—Esther
story) trial data.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2455 Alzheimer's
These ideas will be discussed in the Alzforum Webinar.—Esther Landhuis None
shunted, the only one who didn’t improve was the one who had AD pathology, as well.—Esther Landhuis. See
first clinical trial of CNI-1493 as an AD drug.—Esther Landhuis None
looking at the ADAS-Cog for 15 years.”—Esther Landhuis. None
repeats.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1931 Tau
think we need to pay attention to factors that are important to trial participants.”—Esther Landhuis
ensure that clinical trials adhere to global standards of scientific rigor and ethical behavior.—Esther
beyond which the animals cannot deposit amyloid,” Morgan said.—Esther Landhuis None
for the tau splicing regulatory element.—Esther Landhuis None
an experimental AD drug on Aβ production (Bateman et al., 2009 and ARF related news story).—Esther
2008 and ARF related news story).—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=2335
biomarkers for participant selection (see ARF Live Discussion on biomarkers).—Esther Landhuis None